Palani Kumar Meena Kumari, Halami Prakash Motiram, Serva Peddha Muthukumar
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
Department of Biochemistry, Council of Scientific and Industrial Research, Central Food Technological Research Institute, Mysuru, Karnataka 570020, India.
ACS Omega. 2021 Mar 12;6(11):7701-7710. doi: 10.1021/acsomega.1c00045. eCollection 2021 Mar 23.
MCC2760 is a probiotic strain proven earlier for cholesterol-reducing and anti-inflammatory properties and . This study investigates MCC2760-based probiotic curd in high-cholesterol diet (HCD)-fed C57BL6 mice. The mice were grouped into normal diet control, high-cholesterol diet control, normal diet with probiotic supplementation, and high-cholesterol diet with probiotic supplementation. Control groups and treatment groups were supplemented with market curd and probiotic curd, respectively, via oral gavage for eight weeks. The probiotic count was maintained at 10.95 log CFU/mL in the developed probiotic curd. The HCD group showed an increase in feed intake and body weight. Reduction in the levels of serum cholesterol, triglycerides, low-density lipoprotein cholesterol, glucose, aspartate aminotransferase, and alanine transaminase was observed in probiotic-supplemented groups. The probiotic-supplemented group resulted in an increase in spp. count along with reduced pathogen count in the feces. Probiotic supplementation also showed a reduction in the bacterial translocation count in mesenteric adipose tissue. Expression of inflammatory markers by qPCR showed the decline in the fold change of TNF-α, IL-6, and IL-12 and elevation in the fold change of IL-10 in the adipose tissue of the probiotic-treated group. Probiotic supplementation also improved the expression of GLP-1, ZO-1, and CB2 in the intestine. They were thus possibly playing a role in the enhancement of barrier function. Histopathological sections showed improvement in the cellular infiltration and pathological indications due to the high-cholesterol diet intake. Our study also confirmed that probiotics could increase serum antioxidant enzymes in treated groups, showing their beneficial antioxidant activity. It suggests the anti-inflammatory, antioxidant effect, and gut barrier function of the given probiotic formulation, which ameliorate hypercholesterolemia.
MCC2760是一种益生菌菌株,先前已被证明具有降低胆固醇和抗炎特性。本研究调查了以MCC2760为基础的益生菌凝乳对喂食高胆固醇饮食(HCD)的C57BL6小鼠的影响。将小鼠分为正常饮食对照组、高胆固醇饮食对照组、补充益生菌的正常饮食组和补充益生菌的高胆固醇饮食组。对照组和治疗组分别通过口服灌胃给予市售凝乳和益生菌凝乳,持续八周。在制备的益生菌凝乳中,益生菌数量维持在10.95 log CFU/mL。高胆固醇饮食组的采食量和体重增加。在补充益生菌的组中,观察到血清胆固醇、甘油三酯、低密度脂蛋白胆固醇、葡萄糖、天冬氨酸转氨酶和丙氨酸转氨酶水平降低。补充益生菌的组导致粪便中 spp.数量增加,同时病原体数量减少。补充益生菌还显示肠系膜脂肪组织中的细菌易位数量减少。通过qPCR检测炎症标志物的表达,结果显示益生菌治疗组脂肪组织中TNF-α、IL-6和IL-12的倍数变化下降,而IL-10的倍数变化升高。补充益生菌还改善了肠道中GLP-1、ZO-1和CB2的表达。因此,它们可能在增强屏障功能方面发挥作用。组织病理学切片显示,由于摄入高胆固醇饮食,细胞浸润和病理指征有所改善。我们的研究还证实,益生菌可以增加治疗组的血清抗氧化酶,显示出它们有益的抗氧化活性。这表明给定的益生菌制剂具有抗炎、抗氧化作用以及肠道屏障功能,可改善高胆固醇血症。